FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091249894> ?p ?o ?g. }

• W2091249894 endingPage "93" @default.
• W2091249894 startingPage "83" @default.
• W2091249894 abstract "Several phosphorothioate antisense oligodeoxynucleotides (ODN) are developed to target factors potentially involved in tumor growth and apoptosis suppression. Among them, the 18-mer G3139 (Oblimersen), which targets Bcl-2, is currently being tested in phase II and phase III clinical trials for various tumors in combination with chemotherapy. On the other hand, ODNs containing CpG dinucleotides (CpG-ODN) within specific-sequence contexts (CpG motifs) have been shown to activate rodent or primate immune cells via toll-like receptor 9 (TLR9) and have demonstrated remarkable T cell-dependent antitumor efficacy in a series of murine tumor models. However, immune cell activation by CpG-ODN is largely diminished upon C-5 methylation at CpG cytosine. As G3139 contains CpG motifs, we questioned whether the antitumor effects seen in human tumor xenografts might be abrogated by cytosine C-5 methylation of G3139, which retained the ability of G3139 to suppress Bcl-2 expression in tissue culture, or by similar derivatization of other phosphorothioate ODNs developed for the immune activation of rodent or human cells. The in vivo antitumor efficacy of the immunostimulatory H1826 and H2006 ODNs was compared with that of G3139. Bcl-2 suppression achieved by G3139 purportedly sensitizes tumor cells toward cytotoxic agents, and some of the experiments employed combinations of ODN with such drugs as cisplatin or etoposide. H1826, H2006, and G3139 all produced similar, striking, growth inhibitory effects on either H69 SCLC, A2780 ovarian carcinoma, or A549 lung adenocarcinoma human tumor xenografts at doses of 0.3 mg/kg and 1 mg/kg (H1826, H2006) or 12 mg/kg (G3139) per day. In contrast, the H2006-mC (1 mg/kg) or G3139-mC (12 mg/kg) derivatives demonstrated no significant antitumor effects. The combination of G3139 (12 mg/kg) with cisplatin produced some additive antitumor efficacy, which was not seen in combinations of G3139-mC (12 mg/kg) or H1826 (1 mg/kg) with cisplatin. G3139, at a dose of 12 mg/kg, alone induced extensive enlargement of the spleen. Immunostimulation was evaluated in vitro by flow cytometric measurements of the CD80 and CD86 activation markers found on CD19+ murine splenocytes. The CpG-ODN producing strong antitumor effects in vivo also induced these activation markers in vitro, in contrast to the in vivo inactive G3139-mC. Our data indicate a significant contribution of the immunostimulatory properties of CpG-ODN (including G3139) to the antitumor effects observed in nude mouse xenograft models. This is in contrast to previous data presented by other authors indicating that the activity of G3139 in human tumor xenografts was Bcl-2 specific. Furthermore, as nude mice are devoid of T cells, a T cell-mediated immune response apparently is not required for the potent antitumor responses observed here; innate immune responses are sufficient." @default.
• W2091249894 created "2016-06-24" @default.
• W2091249894 creator A5004982892 @default.
• W2091249894 creator A5011328401 @default.
• W2091249894 creator A5013158876 @default.
• W2091249894 creator A5017114031 @default.
• W2091249894 creator A5028931164 @default.
• W2091249894 creator A5032938103 @default.
• W2091249894 creator A5034547184 @default.
• W2091249894 creator A5038833981 @default.
• W2091249894 creator A5041901534 @default.
• W2091249894 creator A5052922462 @default.
• W2091249894 creator A5055154765 @default.
• W2091249894 creator A5058257943 @default.
• W2091249894 creator A5070500038 @default.
• W2091249894 creator A5072783827 @default.
• W2091249894 creator A5078839117 @default.
• W2091249894 creator A5067034494 @default.
• W2091249894 date "2006-03-01" @default.
• W2091249894 modified "2023-09-24" @default.
• W2091249894 title "G3139 and Other CpG-Containing Immunostimulatory Phosphorothioate Oligodeoxynucleotides Are Potent Suppressors of the Growth of Human Tumor Xenografts in Nude Mice" @default.
• W2091249894 cites W1550494424 @default.
• W2091249894 cites W1917892434 @default.
• W2091249894 cites W1966035396 @default.
• W2091249894 cites W1986974008 @default.
• W2091249894 cites W1996146233 @default.
• W2091249894 cites W2012519514 @default.
• W2091249894 cites W2016696388 @default.
• W2091249894 cites W2023309048 @default.
• W2091249894 cites W2024209493 @default.
• W2091249894 cites W2048842878 @default.
• W2091249894 cites W2061474690 @default.
• W2091249894 cites W2075881778 @default.
• W2091249894 cites W2092347182 @default.
• W2091249894 cites W2103727417 @default.
• W2091249894 cites W2113211717 @default.
• W2091249894 cites W2126397566 @default.
• W2091249894 cites W2128599664 @default.
• W2091249894 cites W2151777859 @default.
• W2091249894 cites W2158044865 @default.
• W2091249894 cites W2158249805 @default.
• W2091249894 cites W2161419307 @default.
• W2091249894 cites W2163172253 @default.
• W2091249894 cites W2169035834 @default.
• W2091249894 cites W2173390962 @default.
• W2091249894 cites W2258156175 @default.
• W2091249894 cites W2338130374 @default.
• W2091249894 cites W2429246466 @default.
• W2091249894 doi "https://doi.org/10.1089/oli.2006.16.83" @default.
• W2091249894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16584297" @default.
• W2091249894 hasPublicationYear "2006" @default.
• W2091249894 type Work @default.
• W2091249894 sameAs 2091249894 @default.
• W2091249894 citedByCount "45" @default.
• W2091249894 countsByYear W20912498942012 @default.
• W2091249894 countsByYear W20912498942013 @default.
• W2091249894 countsByYear W20912498942014 @default.
• W2091249894 countsByYear W20912498942015 @default.
• W2091249894 countsByYear W20912498942016 @default.
• W2091249894 countsByYear W20912498942019 @default.
• W2091249894 crossrefType "journal-article" @default.
• W2091249894 hasAuthorship W2091249894A5004982892 @default.
• W2091249894 hasAuthorship W2091249894A5011328401 @default.
• W2091249894 hasAuthorship W2091249894A5013158876 @default.
• W2091249894 hasAuthorship W2091249894A5017114031 @default.
• W2091249894 hasAuthorship W2091249894A5028931164 @default.
• W2091249894 hasAuthorship W2091249894A5032938103 @default.
• W2091249894 hasAuthorship W2091249894A5034547184 @default.
• W2091249894 hasAuthorship W2091249894A5038833981 @default.
• W2091249894 hasAuthorship W2091249894A5041901534 @default.
• W2091249894 hasAuthorship W2091249894A5052922462 @default.
• W2091249894 hasAuthorship W2091249894A5055154765 @default.
• W2091249894 hasAuthorship W2091249894A5058257943 @default.
• W2091249894 hasAuthorship W2091249894A5067034494 @default.
• W2091249894 hasAuthorship W2091249894A5070500038 @default.
• W2091249894 hasAuthorship W2091249894A5072783827 @default.
• W2091249894 hasAuthorship W2091249894A5078839117 @default.
• W2091249894 hasConcept C104317684 @default.
• W2091249894 hasConcept C140173407 @default.
• W2091249894 hasConcept C150194340 @default.
• W2091249894 hasConcept C150903083 @default.
• W2091249894 hasConcept C153911025 @default.
• W2091249894 hasConcept C154317977 @default.
• W2091249894 hasConcept C190727270 @default.
• W2091249894 hasConcept C202751555 @default.
• W2091249894 hasConcept C203014093 @default.
• W2091249894 hasConcept C207001950 @default.
• W2091249894 hasConcept C22801619 @default.
• W2091249894 hasConcept C2776694085 @default.
• W2091249894 hasConcept C2778239845 @default.
• W2091249894 hasConcept C2779138994 @default.
• W2091249894 hasConcept C33288867 @default.
• W2091249894 hasConcept C502942594 @default.
• W2091249894 hasConcept C54355233 @default.
• W2091249894 hasConcept C55493867 @default.
• W2091249894 hasConcept C86803240 @default.
• W2091249894 hasConcept C8891405 @default.
• W2091249894 hasConceptScore W2091249894C104317684 @default.

• next